Table 1.

Adapted Criteria for Appropriate Prescribing of Dabigatran and Rivaroxaban^7–9,21

Criterion	Patient Factor	CrCl (mL/min)	Indication; Approved Regimen
			THA or TKA	AF	DVT Treatment
Dabigatran
Recommended dose	Age < 75 years	> 50	220 mg daily	110 or 150 mg bid	NA
	Age < 75 years	30–50	150 mg daily	110 or 150 mg bid	NA
	Age ≥ 75 years	> 30	150 mg daily	110 mg bid (≥ 80 years)	NA
Renal failure	NA	< 30	Contraindicated		NA
Interaction, pharmacodynamic	Anticoagulant or thrombolytic		Contraindicated		NA
Transition from anticoagulant	From warfarin		Administer after discontinuation with INR < 2.3		NA
	From SC treatment dose		Administer < 2 h before next expected dose		NA
Interaction, pharmacokinetic	Ketoconazole, dronedarone		Contraindicated		NA
	Amiodarone, quinidine		150 mg daily	Regular dose	NA
	Verapamil	>50	150 mg daily	Regular dose	NA
	Verapamil	30–50	75 mg daily	150 mg bid	NA
Rivaroxaban
Recommended dose		> 50	10 mg daily	20 mg daily	15 mg bid × 3 weeks, then 20 mg daily
		30–50	10 mg daily	15 mg daily	15 mg bid × 3 weeks, then 20 mg daily
Renal failure		< 30
Interaction, pharmacodynamic	Anticoagulant or thrombolytic
Transition from anticoagulant	From warfarin		Administer after discontinuation with INR < 2.3
	From SC treatment dose		Administer < 2 h before next expected dose
Interaction, pharmacokinetic	Ketoconazole, itraconazole, voriconazole, posaconazole
	Ritonavir

AF = atrial fibrillation, CrCl = creatinine clearance, DVT = deep vein thrombosis, INR = international normalized ratio, NA = not applicable, SC = subcutaneous, THA = total hip arthroplasty, TKA = total knee arthroplasty.